Lexeo Therapeutics

Historical price data

Lexeo Therapeutics is a clinical-stage biotech focused on developing AAV-based gene therapies for monogenic cardiovascular diseases and genetically defined CNS disorders. The company has built a promising pipeline, including a Phase 2 candidate for Friedreich's ataxia cardiomyopathy and a Phase 1/2 candidate for APOE4-associated Alzheimer's disease, emerging from foundational research at Weill Cornell Medicine. Its strategy centers on applying validated gene therapy constructs to high-impact, well-defined genetic drivers of disease, aiming for transformative, one-time treatments in areas of significant unmet need. Despite a challenging market valuation, Lexeo represents a focused player in the precision gene therapy space.

AAV-based gene therapy platform utilizing specific serotypes (e.g., cardiotropic AAVrh.10, BBB-penetrant AAV9/hu.68) for targeted delivery of therapeutic transgenes via intravenous or intrathecal routes to treat monogenic diseases.

In cardiology, Lexeo competes with Tenaya Therapeutics and large pharma entrants like Bristol Myers Squibb. In Friedreich's ataxia, it faces Larimar Therapeutics. Its Alzheimer's approach is highly differentiated from mainstream amyloid-targeting biologics, but it must prove clinical efficacy in a field with a high failure rate.